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Lawrence J. Mulligan, PHD,† Kiran Patel, PHD,* Berthold Stegemann, PHD,† Tarek Haddad, MS,†
Russell E. A. Smith, MD,* Sanjay K. Prasad, MD‡
Birmingham and London, United Kingdom; and Minneapolis, Minnesota
Objectives The aim of this study was to determine whether left ventricular (LV) midwall fibrosis, detected by midwall hyperen-
hancement (MWHE) on late gadolinium enhancement cardiovascular magnetic resonance (CMR) imaging, predicts
mortality and morbidity in patients with dilated cardiomyopathy (DCM) undergoing cardiac resynchronization therapy
(CRT).
Background Midwall fibrosis predicts mortality and morbidity in patients with DCM.
Methods Patients with DCM with () or without () MWHE (n  20 and n  77, respectively) as well as 161 patients with
ischemic cardiomyopathy (ICM) undergoing CRT (n  258) were followed up for a maximum of 8.7 years.
Results Among patients with DCM, MWHE predicted cardiovascular mortality (hazard ratio [HR]: 18.6; 95% confidence
intervals [CI]: 3.51 to 98.5; p  0.0008), total mortality or hospitalization for major adverse cardiovascular
events (HR: 7.57; 95% CI: 2.71 to 21.2; p  0.0001), and cardiovascular mortality or heart failure hospitaliza-
tions (HR: 9.56; 95% CI: 2.72 to 33.6; p  0.0004), independent of New York Heart Association class, QRS dura-
tion, atrial fibrillation, LV volumes, LV ejection fraction, and a CMR-derived measure of dyssynchrony. Among
patients with DCM and ICM, the risk of cardiovascular mortality for DCM MWHE (adjusted HR: 18.5; 95% CI:
3.93 to 87.3; p  0.0002) was similar to that for ICM (adjusted HR: 21.0; 95% CI: 5.06 to 87.2; p  0.0001).
Both DCM MWHE and ICM were predictors of pump failure death as well as sudden cardiac death. LV reverse
remodeling was observed in DCM MWHE and in ICM but not in DCM MWHE.
Conclusions Midwall fibrosis is an independent predictor of mortality and morbidity in patients with DCM undergoing CRT.
The outcome of DCM with midwall fibrosis is similar to that of ICM. This relationship is mediated by both pump
failure and sudden cardiac death. (J Am Coll Cardiol 2012;60:1659–67) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.054Cardiac resynchronization therapy (CRT) has revolution-
ized the treatment of selected patients with heart failure
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accepted May 15, 2012.(HF) (1–4). The clinical outcome of CRT, however, is
influenced by the underlying etiology of HF, with an
ischemic etiology being associated with a worse outcome
(5–7). This outcome has been linked to the extent (burden)
and location of myocardial scarring (8–12).
In ischemic cardiomyopathy (ICM), fibrosis usually fol-
lows a subendocardial or transmural distribution, in line
with the perfusion territories of epicardial coronary arteries.
In nonischemic dilated cardiomyopathy (DCM), fibrosis
tends to be patchy, subepicardial, or midmyocardial in
distribution (13–15). It has been shown that non-CRT
patients with DCM and midwall fibrosis have a higher risk
of mortality and unplanned hospitalizations, as well as a
higher risk of sudden cardiac death (16). We hypothesized
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Midwall Fibrosis and CRT October 23, 2012:1659–67that in patients with DCM, the
presence of left ventricular (LV)
midwall fibrosis, assessed using
late gadolinium enhancement
cardiovascular magnetic reso-
nance (LGE-CMR) imaging,
predicts the clinical outcome of
CRT.
Methods
Patients with DCM (n  97) or
ICM (n  161) who were re-
cruited from a single center
(Good Hope Hospital, Birming-
ham, United Kingdom) and who
successfully underwent CRT de-
vice implantation and CMR im-
aging in September 2000 to July
2009 were included in this study.
HF was diagnosed on the basis of
the clinical features plus echocar-
diographic evidence of LV sys-
tolic dysfunction. ICM was diag-
nosed if LV systolic dysfunction
was associated with a history of
myocardial infarction (17) or if
there was significant documented
coronary heart disease. The pat-
tern of LGE on CMR imaging
was also used to differentiate between ICM and DCM (16).
Patients with hypertrophic or restrictive cardiomyopathy,
primary valvular disease, or myocarditis were excluded.
Patients with presumed nonischemic cardiomyopathy with
fibrosis in distributions other than midwall (subepicardial,
epicardial, or patchy) were excluded. The study conformed
with the Declaration of Helsinki. All patients gave written
informed consent, and the study was approved by the local
ethics committee.
Device therapy. In the United Kingdom, the National
Institute of Clinical Excellence guidelines on device therapy
were published in 2007 (18), and therefore, most patients
with either ICM or DCM before 2007 received CRT
pacing (CRT-P). In contrast to other international guide-
lines, National Institute of Clinical Excellence guidelines
recommend CRT-P rather than CRT defibrillation
(CRT-D) in patients with DCM (18). With the exception
of 2 patients who received CRT-D for secondary preven-
tion, all others with DCM received CRT-P.
CRT device implantation was undertaken using standard
techniques under local anesthesia. After implantation, pa-
tients were followed up in a dedicated device therapy clinic
(Good Hope Hospital, Birmingham, United Kingdom).
Clinical response and echocardiographic variables were
assessed at 3 months. Patients in sinus rhythm underwent
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
CRT  cardiac
resynchronization therapy
CRT-D  CRT defibrillation
CRT-P  CRT pacing
DCM  dilated
cardiomyopathy
HF  heart failure
ICM  ischemic
cardiomyopathy
LGE  late gadolinium
enhancement
LV  left ventricular
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
MACE  major adverse
cardiovascular events
MWHE  midwall
hyperenhancement
TSI  tissue
synchronization indextransmitral Doppler-directed optimization of atrioventricu-lar delay using an iterative technique prior to discharge and
at every scheduled visit thereafter. Backup atrial pacing was
set at 60 beats/min, and the pacing mode was set to DDDR
with an interventricular delay of 0 to 4 ms, according to the
manufacturer. In the case of patients in permanent atrial
fibrillation, right ventricular and LV leads were implanted
and a CRT generator was used, with the atrial port plugged
and the generator programmed to a ventricular triggered
mode. Generators used included the Medtronic InSyncIII
models 8040 and 8042, St. Jude Frontier I and II, Vitatron-
CRT 8000, BiotronikStratos LV, and Guidant Contak
Renewal TR2.
Cardiovascular magnetic resonance imaging. CMR im-
aging was performed using a 1.5-T scanner (Signa, GE
Healthcare Worldwide, Slough, United Kingdom) and a
phased-array cardiac coil. A short-axis LV stack was ac-
quired using a steady state in free precession sequence
(repetition time 3.0 to 3.8 ms; excitation time 1.0 ms; image
matrix 224  224; field of view 36 to 42 cm; flip angle 45o)
n sequential 8-mm slices (2-mm interslice gap) from the
trioventricular ring to apex. Acquisition was performed
uring gated 8-s breath-holds (20 phases). Left ventricular
nd-diastolic volume (LVEDV) and left ventricular end-
ystolic volume (LVESV) were quantified using semiauto-
atic manual planimetry of all short-axis steady state in free
recession sequence cine images with MASS analysis soft-
are (Medis, Leiden, the Netherlands). The observer was
linded to echocardiographic and clinical data.
car imaging. For scar imaging using LGE, short-axis slices
dentical to the LV stack were acquired using a segmented
nversion-recovery technique 10 min after the intravenous admin-
stration of gadolinium-diethylenetriaminepentaacetic acid (0.1
mol/kg). Inversion times were adjusted to null normal
yocardium (260 to 400 ms). Scars were classified into
ubendocardial, midwall, epicardial, transmural, or patchy,
ccording to McCrohon et al. (15). Scars in a subendocar-
ial or transmural distribution following coronary artery
erritories were regarded as ischemic in etiology, whereas
idwall scars and absence of scar were regarded as indica-
ive of a nonischemic etiology. Patients were dichotomized
ccording to presence or absence of midwall hyperenhance-
ent (MWHE), assessed visually. Examples of scars typical
f ICM and DCM with MWHE are shown in Figure 1.
car volume was calculated by multiplying the manually
lanimetered area of LGE in each slice by the slice
hickness. Scar burden was expressed as a percentage of LV
yocardial volume in the diastolic phase.
yssynchrony. Intraventricular dyssynchrony was assessed
sing the CMR–tissue synchronization index (TSI), as
reviously described (19). Briefly, segmental radial wall
otion data were quantified for up to 20 phases (time
oints) in each RR interval and fitted to an empirical sine
ave function y  a  b  sin (2t/RR  c). The mean
segmental radial wall motion (a), the segmental radial wall
motion amplitude (b), and the segmental phase shift of the
maximum radial wall motion (c) were extracted from the fit.
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October 23, 2012:1659–67 Midwall Fibrosis and CRTThe CMR-TSI, a global measure of radial dyssynchrony,
was expressed as the standard deviation of all segmental
phase shifts of the radial wall motion extracted from the fit.
This measure was previously shown to predict mortality and
morbidity after CRT (19,20). In a previous study (19),
intraobserver and interobserver variabilities for CMR-TSI
were 3.01% and 8.84%, respectively.
Echocardiography. Two-dimensional echocardiography
was performed using systems 5 and 7 with EchoPAC
(General Electric Healthcare Worldwide). LVEDV and
LVESV were assessed by planimetry of apical 4-chamber
views and the Simpson equation. LV reverse remodeling
was defined as a 15% reduction in LVESV (21) at 3
months.
Clinical response and endpoints. A clinical response to
CRT was quantified in terms of the composite clinical score,
according to which response was defined as survival with
freedom from HF hospitalizations for 1 year after implan-
tation as well as improvement by 1 New York Heart
Figure 1 Patterns of Myocardial Scarring in Ischemic and Noni
(A) Short-axis inversion-recovery late gadolinium enhancement cardiovascular mag
in a patient with ischemic cardiomyopathy. (B) Short-axis inversion-recovery LG
ischemic cardiomyopathy. (C) Four-chamber and (D) short-axis inversion-recovery L
dilated cardiomyopathy.Association (NYHA) functional class or by 25% increasein 6-min walking distance. The primary endpoint was
cardiovascular death (including transplantation). Secondary
endpoints included death from any cause, the composite
endpoints of cardiovascular death/unplanned hospitaliza-
tion for worsening HF, death from any cause/unplanned
hospitalization for major adverse cardiovascular events
(MACE), and sudden cardiac death/hospitalization for
major arrhythmic events. Hospitalizations for worsening
HF, myocardial infarction, unstable angina, arrhythmia,
stroke, or pulmonary embolism were included in this endpoint.
The first event was included in the analysis. Sudden cardiac
death was defined as a “natural, unexpected death due to
cardiac causes, heralded by an abrupt loss of consciousness
within 1 hour of the onset of acute symptoms” (22). Death
from pump failure was defined as “death after a period of
clinical deterioration in signs and symptoms of heart failure
despite medical treatment” (23). Mortality data was col-
lected prospectively through medical records and, when
appropriate, from interviews with patients’ caregivers. Clin-
ic Cardiomyopathy
esonance (LGE-CMR) image showing a transmural, inferior myocardial infarction
image showing a transmural, anterior myocardial infarction in a patient with
R images showing midwall LGE, denoting fibrosis, in a patient with idiopathicschem
netic r
E-CMR
GE-CMical outcome data were collected every 3 months by an
0
m
u
1
s
R
B
p
A
D
(
m
t
v
1662 Leyva et al. JACC Vol. 60, No. 17, 2012
Midwall Fibrosis and CRT October 23, 2012:1659–67investigator who was blinded to clinical and imaging data.
Events were adjudicated by the investigators (P.W.F. and
F.L.) every 3 months.
Statistical analysis. Continuous variables are expressed as
mean  SD. Normality was tested using the Shapiro-Wilk
test. Comparisons between normally distributed continuous
variables were made using analysis of variance with the
Scheffe F procedure for multiple comparisons. Variables
that did not follow a normal distribution, such as NT
pro–brain natriuretic peptide, were log-transformed for
statistical analyses. Categorical variables were analyzed us-
ing chi-square tests and the Scheffe post hoc test. Changes
in variables from baseline to follow-up were analyzed using
paired t tests and Wilcoxon matched-pairs analyses. The
ability of MWHE to predict the various endpoints was
assessed using Kaplan-Meier survival curves and the log-
rank (Mantel-Cox) test, as well as Cox proportional hazards
analyses. For large estimates of the coefficient, as in our case
of sudden cardiac deaths in the DCMMWHE group, the
standard error is typically inflated, resulting in a lower Wald
statistic, falsely considering the variable not relevant in the
Characteristics of the Study GroupsTable 1 Characteristics of the Study Groups
Group A
DCM MWHE
Group
DCM M
N 20 77
Age, yrs 63.6 9.58 66.7
Men 12 (60) 48 (6
NYHA functional class 3.50 0.51 3.21
III 10 (50) 61 (7
IV 10 (50) 16 (2
Systolic blood pressure, mm Hg 103.7 (14.6) 120.8 (1
Diastolic blood pressure, mm Hg 63.7 (11.3) 73.5 (1
NT pro-BNP, ng/l 5,045.9 (1,027.9) 1,838.3 (2
Creatinine, mol/l 130.8 (56.1) 103.2 (3
eGFR 56.6 (26.6) 67.3 (2
CRT-D 0 2 (2
Comorbidity
Diabetes mellitus 1 (5) 12 (1
Hypertension 4 (20) 22 (2
Coronary artery bypass graft 0 0
Medication
Loop diuretics 20 (100) 61 (7
ACEIs or ARBs 17 (85) 73 (9
Beta-blockers 11 (55) 39 (5
Aldosterone antagonists 8 (40) 32 (4
ECG variables
Permanent atrial fibrillation 3 (15) 16 (2
QRS duration, ms 154.1 35.5 144.2
CMR variables
LVEDV, ml 314.0 107.6 205.6
LVESV, ml 269.4 103.2 166.5
LVEF, % 16.0 6.06 23.9
CMR-TSI, ms 91.8 31.9 75.8
Values are mean  SD or n (%). *Differences between the groups from analysis of variance with
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; BNP herapy defibrillation; DCM  dilated cardiomyopathy; ECG  electrocardiography; eGFR  estimated g
olume; LVEF left ventricular ejection fraction; LVESV left ventricular end-systolic volume; MWHEmidmodel. To overcome this, we used the likelihood ratio test,
which is considered superior for testing the Cox regression
model. The profile likelihood was used to estimate the lower
95% confidence interval (CI) bound. Variables reaching p
.10 on univariate analyses were considered for entry in
ultivariable models. Statistical analyses were performed
sing Statview (Cary, North Carolina) and SPSS version
5.0 (Chicago, Illinois). A 2-tailed p 0.05 was considered
tatistically significant.
esults
aseline characteristics. The baseline characteristics of
atients with ICM and DCM are shown in Table 1.
mong the entire cohort, 20 of 258 patients (7.8%) with
CM had MWHE. Of the 97 patients with DCM, 20
26%) had MWHE, and the rest of the DCM group had no
yocardial scarring at all. The DCMMWHE and DCM
MWHE groups were well matched for age, device type,
comorbidities, presence of permanent atrial fibrillation, and
QRS duration. The MWHE group had a worse NYHA
Group C
ICM
p Value*
A vs. B A vs. C B vs. C
161
69.3 9.4 0.25 0.09 0.10
142 (88.2) 0.85 0.0008 0.0001
3.25 0.44 0.03 0.0428 0.84
122 (76)
39 (24)
119.5 (20.4) 0.0048 0.0061 0.69
70.3 (11.6) 0.008 0.06 0.09
) 3,117.2 (4,108.9) 0.0064 0.07 0.07
122.0 (37.1) 0.0070 0.36 0.0013
58.8 (20.5) 0.06 0.68 0.0082
33 (20.4) 0.4664 0.0657 0.0006
33 (20.4) 0.22 0.09 0.32
46 (28.6) 0.44 0.38 0.90
54 0.0017 0.0001
140 (87.0) 0.0257 0.09 0.10
148 (92) 0.13 0.25 0.51
102 (63.4) 0.73 0.45 0.05
60 (37.2) 0.88 0.92 0.78
27 (16.7) 0.74 0.84 0.22
136.9 32.6 0.4 0.08 0.24
230.6 97.5 0.0001 0.0018 0.18
194.5 89.4 0.0001 0.0022 0.08
23.9 10.9 0.0007 0.0053 0.99
108.6 44.7 0.44 0.36 0.0001
effe post hoc test for continuous variables and from chi-square tests for categorical variables.
triuretic peptide; CMR  cardiovascular magnetic resonance; CRT-D  cardiac resynchronizationB
WHE
13.0
2)
0.41
9)
1)
8.4)
2.8)
,012.7
3.4)
0.8)
.6)
6)
9)
9)
5)
1)
2)
1)
29.1
79.7
74.2
9.7
33.8
the Sch
brain nalomerular filtration rate; ICM  ischemic cardiomyopathy; LVEDV  left ventricular end-diastolic
wall hyperenhancement; NYHA New York Heart Association; TSI tissue synchronization index.
lnd CM
er abbr
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October 23, 2012:1659–67 Midwall Fibrosis and CRTclass (p  0.0271) and LV ejection fraction (LVEF) (p 
0.0007), a higher LVEDV and LVESV (both p  0.0001),
ower systolic (p  0.0048) and diastolic (p  0.008) blood
pressures, higher NT pro–brain natriuretic peptide levels
(p  0.0064), higher plasma creatinine levels (p  0.0070),
but similar estimated glomerular filtration rates than the
DCM MWHE group. These groups were also matched
for treatment with angiotensin-converting enzyme inhibi-
tors/angiotensin receptor antagonists, beta-blockers, and
aldosterone antagonists, but theMWHE group was more
likely to require loop diuretics (p  0.0257). In comparison
with the DCM groups, the ICM group had a higher
proportion of men and was more likely to receive CRT-D
(as required by contemporaneous guidelines) but was well
matched to the DCM MWHE for age, medication, and
LV volumes and LVEF. The CMR-TSI was higher in the
ICM group than in the DCM MWHE group (p 
0.0001).
Endpoints. After a maximum follow-up period of 3,166
days (8.7 years; median follow-up time 1,038 days [2.84
years]), total mortality was 10 of 20 (50%) in DCM
MWHE and 5 of 77 (6.5%) in DCM MWHE.
Cardiovascular mortality was 9 of 20 (45%) and 2 of 77
(2.6%) in the DCM MWHE and DCM MWHE
groups, respectively. In the ICM group, total mortality was
53 of 161 (31.8%) and cardiovascular mortality was 49 of
161 (30.4%).
Among patients with DCM, MWHE predicted car-
Cox Proportional Hazards Analyses of Baseline Variables in RelatioTable 2 Cox Proportional Hazards Analyses of Baseline Variabl
Cardiovascular Mortality
HR (95% CI)* p Value
Univariate analyses
MWHE 22.0 (4.73–102.0) 0.0001
NYHA functional class III 0.41 (0.12–1.33) 0.13
QRS duration, ms 1.02 (1.00–1.05) 0.0339
Permanent atrial fibrillation 0.77 (0.17–3.57) 0.73
LVESV, ml 1.01 (1.00–1.01) 0.0232
LVEDV, ml 1.01 (1.00–1.01) 0.0181
LVEF, % 0.93 (0.86–1.01) 0.08
CMR-TSI, ms 1.04 (0.99–1.08) 0.09
Multivariable analyses†
Model 1
MWHE 18.6 (3.51–98.5) 0.0008
NYHA functional class III —
QRS duration, ms 1.01 (0.99–1.03) 0.16
LVEF, % 0.99 (0.91–1.09) 0.92
Model 2
MWHE 18.7 (3.53–98.7) 0.0008
NYHA functional class III —
QRS duration, ms 1.01 (0.99–1.03) 0.16
CMR-TSI, ms 1.00 (0.96–1.05) 0.93
*Only variables with p  0.10 on univariate analyses were included in multivariable models. Varia
†In addition to MWHE, includes NYHA class, QRS duration, presence of atrial fibrillation, LVEF, a
CI  confidence interval; HR  hazard ratio; MACE  major adverse cardiovascular events; othdiovascular mortality (hazard ratio [HR]: 18.1; p 0.0001),the composite of total mortality or hospitalization for
MACE (HR: 7.57; p  0.0001), and the composite
endpoint of cardiovascular mortality or HF hospitalizations
(HR: 9.90; p 0.0004), independent of NYHA class, QRS
duration, presence of atrial fibrillation, LV volumes, LVEF,
and CMR-TSI (Table 2).
Kaplan-Meier survival curves for the DCM and ICM
groups are shown in Figure 2. In multivariable analyses
comprising the DCM and ICM subgroups, both DCM
MWHE (HR: 18.5 in model 1; HR: 18.6 in model 2;
both p  0.0002) and ICM (HR: 21.0; p  0.0001)
emerged as strong predictors of cardiovascular mortality,
independent of NYHA class, treatment with beta-blockers,
QRS duration, presence of atrial fibrillation, LV volumes,
LVEF, and CMR-TSI (Table 3).
Scar burden in the DCM group was 2.12%  4.96%
(range 0 to 26.9%). In Cox proportional hazards analyses,
scar burden did not emerge as a predictor of total mortality
(HR: 0.99; 95% CI: 0.87 to 1.14; p  0.94) or cardiovas-
cular mortality (HR: 1.02; 95% CI: 0.89 to 1.16; p  0.82).
Pump failure. Of the 60 cardiovascular deaths, 46 were
due to pump failure (DCM MWHE 6 of 20 [30%];
DCM MWHE 2 of 77 [2.6%]; ICM 38 of 161 [23.6%]).
In univariate analyses comprising the DCM and ICM
subgroups, both ICM (HR: 10.5; 95% CI: 2.52 to 43.5; p
0.0012) and DCM MWHE (HR: 14.1; 95% CI: 2.85 to
70.0; p  0.0012) emerged as predictors of death from
Clinical Outcome in Patients With DCMRelation to Clinical Outcome in Patients With DCM
Total Mortality or
Hospitalizations for MACE
Cardiovascular Mortality or
Heart Failure Hospitalizations
HR (95% CI)* p Value HR (95% CI)* p Value
.24 (3.09–16.9) 0.0001 11.9 (4.09–34.7) 0.0001
.56 (0.24–1.43) 0.19 0.29 (0.11–0.78) 0.014
.01 (1.00–1.03) 0.11 1.02 (1.00–1.04) 0.07
.99 (0.36–2.68) 0.97 0.74 (0.21–2.59) 0.63
.00 (0.99–1.01) 0.12 1.01 (1.00–1.01) 0.0316
.00 (0.99–1.01) 0.13 1.00 (1.00–1.01) 0.0297
.97 (0.92–1.01) 0.16 0.95 (0.89–1.01) 0.08
.02 (0.99–1.04) 0.17 1.03 (0.99–1.06) 0.08
.57 (2.71–21.2) 0.0001 9.56 (2.72–33.6) 0.0004
— 0.58 (0.21–1.66) 0.31
— 1.01 (0.99–1.02) 0.44
— 1.00 (0.94–1.07) 0.95
.57 (2.71–21.2) 0.0001 9.62 (2.74–33.8) 0.0004
— 0.59 (0.21–1.65) 0.31
— 1.01 (0.99–1.02) 0.45
— 1.00 (0.97–1.03) 0.94
t interacted with each other, such as LV volumes, were excluded from the multivariable analyses.
R-TSI as independent variables. None of the latter reached statistical significance.
eviations as in Table 1.n toes in
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cardiovascular deaths, 14 were sudden cardiac deaths (DCM
MWHE 3 of 20 [15%]; DCM MWHE 0 of 77 [0%];
ICM 11 of 161 [6.8%]). In univariate and multivariate
analyses comparing with DCM MWHE, both DCM
MWHE and ICM significantly improved the Cox regres-
sion model using the likelihood ratio test (p  0.0029), and
both DCM MWHE (HR lower 95% CI: 2.65) and ICM
(HR lower 95% CI: 4.54) emerged as predictors of sudden
cardiac death.
Five patients had unplanned hospitalizations for major
arrhythmic events (DCM MWHE 1 of 20 [5.0%] for
atrial fibrillation; DCM MWHE 1 of 77 [1.3%]; ICM 1
atrial fibrillation, 1 ventricular tachycardia, and 1 ventricular
fibrillation [total 3 of 161 (5.0%)]). In univariate analyses
comprising the DCM and ICM subgroups, DCM
MWHE emerged as a predictor of sudden cardiac death
or major arrhythmic events (HR: 16.7; 95% CI: 1.87 to
149.7; p  0.0118), whereas ICM reached only borderline
significance (HR: 7.03; 95% CI: 0.92 to 53.4; p  0.06). In
univariate analyses comprising the DCM subgroups, DCM
Cox Proportional Hazards Analyses ofBaseline Variables in Relation to CardiovascularMortality in Pati nts With DCM or ICM
Table 3
Cox Proportional Hazards An lyses of
Baseline Variables in Relation to Cardiovascular
Mortality in Patients With DCM or ICM
Cardiovascular Mortality
HR (95% CI)* p Value
Univariate analyses
DCM MWHE 24.1 (5.20–111.7) 0.0001
ICM 14.3 (3.46–58.7) 0.0002
NYHA functional class 2.07 (1,23–3.48) 0.0063
Beta-blocker, no 1.68 (1.01–2.79) 0.0451
QRS duration, ms 1.01 (1.00–1.02) 0.06
Permanent atrial fibrillation 1.23 (0.68–2.24) 0.49
LVESV, ml 1.00 (1.00–1.01) 0.0039
LVEDV, ml 1.00 (1.00–1.01) 0.0087
LVEF, % 0.95 (0.92–0.98) 0.0018
CMR-TSI, ms 1.01 (1.01–1.02) 0.0001
Multivariable analyses†
Model 1
MWHE 18.5 (3.93–87.3) 0.0002
ICM 21.0 (5.06–87.2) 0.0001
NYHA functional class 1.55 (0.88–2.75) 0.13
Beta-blocker use, no 2.28 (1.32–3.93) 0.0031
QRS duration, ms 1.01 (1.00–1.02) 0.07
LVEF, % 0.96 (0.93–0.99) 0.0281
Model 2
MWHE 18.6 (3.94–87.4) 0.0002
ICM 21.0 (5.07–87.3) 0.0001
NYHA functional class 1.55 (0.88–2.75) 0.13
Beta-blocker use, no 2.28 (1.32–3.93) 0.0031
QRS duration, ms 1.01 (1.00–1.02) 0.07
CMR-TSI, ms 1.02 (1.00–1.03) 0.0282
*Only variables with p  0.10 on univariate analyses were included in multivariable models.
Variables that interacted with each other, such as LV volumes, were excluded from the multivari-
able analyses. †In addition to MWHE, includes NYHA class, QRS duration, presence of atrial
fibrillation, LVEF, and CMR-TSI as independent variables. None of the latter reached statisticalFigure 2 Survival Curves After
Cardiac Resynchronization Therapy
Patients with dilated cardiomyopathy (DCM) were categorized according to pres-
ence of midwall fibrosis (midwall hyperenhancement [MWHE]) or absence of
scar (MWHE). ICM  ischemic cardiomyopathy; MACE  major adverse car-
diovascular events.significance.
Abbreviations as in Tables 1 and 2.
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October 23, 2012:1659–67 Midwall Fibrosis and CRTMWHE emerged as a predictor of sudden cardiac death
or major arrhythmic events (HR: 16.1; 95% CI: 1.81 to
144.8; p  0.0128).
Clinical variables. Whereas no significant changes in
NYHA class were observed in the DCM MWHE group
(1.25; p  0.17) or the DCM MWHE group (1.20;
p  0.07), a significant reduction in NYHA class was
bserved in the ICM group (1.10; p  0.0429). The
6-min walking distance, however, increased in all groups
(DCM MWHE 101.6  75.8 m, p  0.0007; DCM-
MWHE 54.9  74.2 m, p  0.0001; ICM 63.1 
98.17, p  0.0001). Quality of life scores (a reduction
denoting an improvement in quality of life) decreased in all
groups (DCM MWHE 13.7  40.6, p  0.0202; DCM
MWHE 25.7  29.6, p  0.0001; ICM 18.5  21.7,
 0.0001). Responder rates, in terms of the clinical
composite score, were similar across the groups (DCM
MWHE 65.0%; DCM MWHE 80.5%; ICM 68.2%;
p  0.19).
Echocardiographic variables. As shown in Figure 3, LV
reverse remodeling, defined as a 15% reduction in
LVESV, was observed in the DCM MWHE (p 
0.0007) and ICM groups (p 0.0428) but not in the DCM
MWHE group. Similarly, significant reductions in the
VEDV were observed in the DCMMWHE group (p
.0019) and the ICM group (p  0.0238) but not in the
CMMWHE group. The LVEF increased in the DCM
MWHE group (p  0.0395) and the ICM group (p 
.05) but not in the DCM MWHE group.
iscussion
e have shown that in patients with DCM, midwall fibrosis
detected by MWHE on LGE-CMR imaging) predicts mor-
ality and morbidity after CRT. Compared with patients
ithout midwall fibrosis, patients with midwall fibrosis were
8 times more likely to die from cardiovascular causes after
djustment for NYHA class, beta-blocker use, QRS duration,
trial fibrillation, LVEF, and dyssynchrony. Midwall fibrosis
as also predictive of the combined endpoint of total mortality
r hospitalizations for MACE and the combined endpoint of
ardiovascular mortality or HF hospitalizations. Patients with
idwall fibrosis were less likely to exhibit LV reverse remod-
ling, assessed by echocardiography.
A novel finding from this study is that the outcome after
RT of patients with midwall fibrosis was similar to that of
atients with ICM. Conversely, the outcome of patients
ith DCM and without midwall fibrosis was dramatically
etter. These findings have emerged in the context of major
RT trials showing that patients with nonischemic DCM
ave a better clinical outcome (5), as well as a better LV
everse remodeling response (6,7,24) to CRT. Importantly,
owever, no major trial has used CMR in the characteriza-
ion of the etiology of HF nor have they used CMR in the
ifferentiation between DCM with and without midwall
brosis. It therefore remains unknown whether the super-Figure 3 Echocardiographic Response to
Cardiac Resynchronization Therapy
Changes from baseline are shown in box and whisker plots, in which the 5 hor-
izontal lines represent the 10th, 25th, 50th, 75th, and 90th percentiles from
bottom to top. For left ventricular (LV) volumes, the change is shown in terms
of the percent change in relation to baseline volumes. For left ventricular ejec-
tion fraction (LVEF), changes are shown in terms of the absolute percentage
change. LVEDV  left ventricular end-diastolic volume; LVESV  left ventricular
end-systolic volume; other abbreviations as in Figure 2.
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Midwall Fibrosis and CRT October 23, 2012:1659–67responders to CRT described in such studies are patients
with DCM without midwall fibrosis. Our findings have
major implications for prognostic stratification in clinical
practice as well for the design of CRT outcome trials. It
would appear that patients with DCM without midwall
fibrosis have a particularly low clinical event rate.
Since its description in autopsy studies (25) and in an
LGE-CMR study (15), midwall fibrosis has been recognized
as a prognostic marker for patients with DCM. A prospective
cohort study of 65 patients with nonischemic DCM and
LVEF 35% undergoing implantable cardioverter defibrilla-
or therapy showed that LGE on CMR in any distribution was
ssociated with an 8.2-fold increase in the risk of the composite
ndpoint of hospitalization for HF, appropriate implantable
ardioverter defibrillator shocks, and cardiac death (26). Asso-
ull et al. (16) showed that MWHE on LGE-CMR pre-
icted the risk of death or hospitalizations in non-CRT
atients with DCM. Our findings are largely consistent with
hese studies and extend the application of this technique to
he risk stratification of patients undergoing CRT.
We found that the degree of dyssynchrony was similar in
he MWHE and MWHE groups. Yet, the clinical
utcome was worse in the MWHE group. This suggests
hat the detrimental effects of midwall fibrosis on clinical
utcome is mediated through mechanisms that are indepen-
ent of dyssynchrony. Several aspects may be relevant in this
espect. Fibrosis effectively replaces viable myofibrils, thus
educing the amount of functional myocardium. It interacts
echanically with the complex fiber architecture of the
yocardium, which may lead to global mechanical effects
emote from the affected area, such as LV stiffness, reduced
ompliance, and reduced contractile reserve. The observa-
ion that patients with midwall fibrosis did not exhibit LV
everse remodeling or an improvement in LVEF is consis-
ent with this notion. Myocardial scars are not readily
xcitable (27,28) and therefore reduce the volume of excit-
ble myocardium available to ventricular depolarization.
It has been shown that myocardial fibrosis can form a
ubstrate for ventricular arrhythmias (29,30). Accordingly,
idwall fibrosis has been linked to a higher risk of sudden
ardiac death in patients with DCM. We too have found
hat midwall fibrosis predicts sudden cardiac death, as well
s the composite endpoint of sudden cardiac death or major
rrhythmic events. In fact, the association between midwall
brosis (HR: 16.7; p  0.0118) and this endpoint was
stronger than for ICM (HR: 7.03; p  0.0597). The
ccurrence of only 3 sudden cardiac deaths in the whole
CM group in this study, however, precluded reliable
tatistical analysis of midwall fibrosis in relation to sudden
ardiac death. On the other hand, the LVEF was very low
16%) in comparison with that of CRT-D trials (20% to
2%) (2), and deaths from pump failure occurred relatively
arly in the follow-up period. Therefore, the possibility
rises that patients succumbed to pump failure before the
ccurrence of lethal ventricular arrhythmias.Despite worse outcomes, the symptomatic response in
patients with midwall fibrosis was similar to that in patients
without midwall fibrosis. This discordance between out-
comes and symptomatic response after CRT is well recog-
nized. Yu et al. (21), for example, found no relationship
between LV reverse remodeling and changes in NYHA
class, 6-min walking distance, or quality of life scores after
CRT. Ypenburg et al. (31) also showed similar improve-
ment in NYHA class, quality of life scores, and 6-min
walking distance in patients exhibiting 15% reduction in
LVESV and in those exhibiting a reduction in LVESV of
14% after CRT. Foley et al. (32) found similar symptom-
atic response rates in survivors and nonsurvivors 1 year after
CRT device implantation. There is, in addition, evidence of
a discordance between outcomes and symptomatic response
according to etiology. In the REVERSE (Resynchroniza-
tion Reverses Remodeling in Systolic Left Ventricular
Dysfunction) study, in which patients in NYHA class I or II
and LVEF 40% were randomized to CRT or no CRT for
12 months, HF etiology was not predictive of the composite
clinical response (24). This is in keeping with our finding of
similar symptomatic response rates in patients with and
without midwall fibrosis.
Clinical application. CMR has already gained credence as
an ideal investigation for patients with HF because it provides
unparalleled quality of information on cardiac function and
disease etiology. In addition, LGE-CMR is also unique in its
ability to allow quantification and localization of myocardial
scarring in patients with ICM, in whom it has proven to be
valuable in prognostic stratification (8,10,11). Our findings
extend the utility of CMR to the prognostic stratification of
patients with DCM undergoing CRT.
Study limitations. This study was observational and did
not include a control group on maximum tolerated phar-
macological therapy only. We therefore cannot ascertain
whether patients with MWHE have a worse outcome than
patients not undergoing CRT, and we cannot therefore
assume that patients with MWHE do not benefit from
CRT. In addition, the number of patients in the MWHE
group was small. Therefore, the lack of an effect of CRT on
LV reverse remodeling may be attributable to statistical
underpowering. Moreover, we have not quantified the
severity of mitral regurgitation, which could also contribute
to differences in outcomes between the groups. The lack of
systematic collection of arrhythmic events at device inter-
rogation is also a limitation. The relatively small number of
events in some multivariable models render these liable to
overfitting, and further validation is desirable. The strength
of the association between the DCM MWHE group and
the various endpoints is, however, unlikely to be affected by
further validation. In contrast to other studies in patients
with DCM (16) or coronary heart disease (33), we have not
found a graded relationship between scar burden and
mortality in patients with DCM. This, however, is likely to
be due to statistical underpowering.
1667JACC Vol. 60, No. 17, 2012 Leyva et al.
October 23, 2012:1659–67 Midwall Fibrosis and CRTConclusions
We conclude that midwall fibrosis, detected by MWHE on
LGE-CMR, is a powerful predictor of mortality and morbid-
ity in patients with DCM undergoing CRT, independent of
QRS duration, NYHA class, LVEF, atrial fibrillation, LV
volumes, and mechanical dyssynchrony. Pump failure as well as
sudden cardiac death and arrhythmic events mediate this
association. These findings provide further evidence for CMR
in the prognostic stratification of patients undergoing CRT.
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